Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05864742 |
| Title | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (+/-Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Peter MacCallum Cancer Centre, Australia |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | AUS |